NCT01375127

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

An Observational Study To Collect Follow-up Clinical Data From Kidney Transplant Recipients Who Received Tofacitinib (CP-690,550) In Completed Phase 2 Studies

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 83 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

Detailed description

Subjects are identified based on whether they received tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or who did not elect to enroll in long-term extension studies. Subjects are pre-identified

Conditions

• Kidney Transplantation

Interventions

Type	Name	Description
DRUG	Tofacitinib	Subjects who previously took 15 mg BID or 30 mg BID
DRUG	Tofacitinib	Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2011-06-17
• Last updated: 2013-10-29
• Results posted: 2013-08-14

Locations

43 sites across 12 countries: United States, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Spain